Skip to main content

Table 7 Percentage growth inhibitory effect of herbal combination against different human cell lines

From: Development of aqueous-based multi-herbal combination using principal component analysis and its functional significance in HepG2 cells

Conc. (μg/ml)

MCa

NMCb

MG-63

IMR-32

HeLa

A-549

HepG2

293 T

Inhibition (% ± SE)

31.25

32.947 ± 0.809

08.141 ± 1.339

13.583 ± 0.676

15.487 ± 0.366

36.338 ± 0.972

1.695 ± 0.676

62.5

34.090 ± 0.024

20.261 ± 0.235

31.336 ± 0.821

27.051 ± 1.012

44.376 ± 0.570

2.452 ± 0.567

125

37.926 ± 0.280

32.510 ± 0.284

34.619 ± 0.911

46.275 ± 0.411

60.264 ± 0.247

5.510 ± 0.440

250

41.271 ± 0.512

50.335 ± 0.598

47.664 ± 0.903

60.716 ± 0.171

67.763 ± 0.027

7.206 ± 0.621

500

51.194 ± 0.537

63.810 ± 0.402

59.736 ± 0.671

68.883 ± 0.230

84.514 ± 0.021

8.689 ± 0.813

1000

75.440 ± 0.368

71.598 ± 0.257

63.992 ± 0.677

74.007 ± 0.106

95.448 ± 0.011

9.658 ± 0.424

Regression equation

y = 0.043x + 31.28

y = 19.19ln(x) - 58.24

y = 14.43ln(x) - 32.89

y = 17.82ln(x) - 43.52

y = 17.45ln(x) - 25.54

y = 2.482ln(x) - 6.976

R2

0.995

0.991

0.970

0.964

0.991

0.971

IC50 (μg/ml)

435.349

281.586

312.399

189.025

75.864

9.322 × 109

Camptothecin (10 μM)

81.86

65.68

71.60

68.07

68.13

22.62

  1. aMalignant cells; bNon-malignant cell